Stock comparison
GSK
Mettler-Toledo International
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
GSK
GSK
Market cap
$103.33B
Sector
Healthcare
MTD
Mettler-Toledo International
Market cap
$22.29B
Sector
Healthcare
Overall winner
Mettler-Toledo International MTD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | GSK | MTD | Winner |
|---|---|---|---|
| Warren Buffett | 58C | 69B | MTD |
| Benjamin Graham | 62C | 65B | MTD |
| Philip Fisher | 66B | 63C | GSK |
| Peter Lynch | 47D | 66B | MTD |
| Joel Greenblatt | 35D | 68B | MTD |
| Charlie Munger | 65C | 74B | MTD |
| Terry Smith | 63C | 70B | MTD |
Side-by-side metrics
| Metric | GSK | MTD |
|---|---|---|
| Market cap | $103.33B | $22.29B |
| P/E (TTM) | 12.9x | 25.3x |
| EV/EBIT | 10.8x | 21.6x |
| ROIC (TTM) | 13.76% | 36.09% |
| Gross margin | 72.74% | 57.79% |
| Net margin | 17.78% | 21.4% |
| Revenue CAGR 5y | 7.24% | 2.01% |
| EPS CAGR 5y | 19.78% | 6.12% |
| Debt / Equity | 1.1x | - |
| Dividend yield | 3.6% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
GSK leads on
- Dividend yield3.6%vs 0.0%+100%
- Market cap$103.33Bvs $22.29B+78%
- Revenue CAGR 5y7.24%vs 2.01%+72%
- EPS CAGR 5y19.78%vs 6.12%+69%
MTD leads on
- Debt / Equity-vs 1.1x+102%
- ROIC (TTM)36.09%vs 13.76%+62%
- Net margin21.4%vs 17.78%+17%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.